Cat No.：31840 ★Download Datasheet★
INTRODUCTION
Glutamic acid decarboxylase autoantibodies (GADA) are found in 70% to 80% of individuals with new-onset type 1 diabetes, making
it the most frequent autoantibody in autoimmune diabetes.
GADA can be detected in serum for many years post diagnosis, and high concentrations of GADA have been considered as a marker of faster β-cell exhaustion in these patients.
Furthermore, GADA in non-diabetic individuals predicts the later development of type 1 diabetes1.
Besides autoimmune diabetes, GADA also exists in Stiff Man Syndrome, autoimmune poly-endocrinopathies, and some of Grave’s
Disease patients2.
Assay Characteristics:
Sample Type: Serum and plasma
References:
1. Liu B, et al. Past, present and future of latent autoimmune diabetes in adults. Diabetes Metab Res Rev. 2019 Jul 18:e3205.
2. Björk E, et al. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes.
Diabetes. 1994 Jan;43(1):161-5.